Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.6 GBX | +28.78% | +12.34% | -24.57% |
05-03 | Ondine Biomedical shares rise on fundraise to advance Steriwave | AN |
05-03 | Ondine Biomedical to Raise GBP3 Million Via Placing, Subscription | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-24.57% | 18.78M | - | ||
-3.79% | 184B | C+ | ||
-0.84% | 108B | C | ||
-3.75% | 67.82B | A | ||
+3.45% | 51.05B | B- | ||
+9.04% | 44.67B | B- | ||
+3.40% | 41.78B | B+ | ||
+3.21% | 26.78B | B | ||
+3.66% | 26.59B | A- | ||
+15.23% | 25.86B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- OBI Stock
- Ratings Ondine Biomedical Inc.